| First Author | Clark-Knowles KV | Year | 2018 |
| Journal | Exp Cell Res | Volume | 371 |
| Issue | 1 | Pages | 83-91 |
| PubMed ID | 30059665 | Mgi Jnum | J:268083 |
| Mgi Id | MGI:6270838 | Doi | 10.1016/j.yexcr.2018.07.043 |
| Citation | Clark-Knowles KV, et al. (2018) Modulating SIRT1 activity variously affects thymic lymphoma development in mice. Exp Cell Res 371(1):83-91 |
| abstractText | SIRT1 is a protein deacetylase with a broad range of biological functions, many of which are known to be important in carcinogenesis, however much of the literature regarding the role of SIRT1 in cancer remains conflicting. In this study we assessed the effect of SIRT1 on the initiation and progression of thymic T cell lymphomas. We employed mouse strains in which SIRT1 activity was absent or could be reversibly modulated in conjunction with thymic lymphoma induction using either the N-nitroso-N-methylurea (NMU) carcinogenesis or the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) transgene. Decreased SIRT1 activity reduced the development of thymic lymphomas in the NMU-treated mice but was permissive for the formation of lung adenomas. Conversely, in the NPM-ALK transgenic mice, decreased SIRT1 activity had a modest promoting effect in the development of thymic lymphomas. The results of the work presented here add to the growing body of evidence that sirt1 is neither an outright oncogene nor a tumor suppressor. These opposing results in two models of the same disease suggest that the influence of sirt1 on carcinogenesis may lie in a role in tumor surveillance. |
